Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Mabwell Stages $547 Million IPO on STAR Board for Antibody Portfolio

publication date: Jan 20, 2022

Mabwell (Shanghai) Bioscience completed a $547 million IPO on Shanghai's STAR Board. Established in 2017, Mabwell is a clinical-stage antibody developer with 15 assets in its pipeline: three are in BLA stage, three in pivotal trials and six in Phase I/II trials. The company's lead candidates are biosimilars. It develops therapies for indications in auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases. The company has a wholly-owned US subsidiary, Mabwell Therapeutics, in San Diego. Mabwell's shares have fallen 22% below their IPO price. More details....

Stock Symbol: (SHA: 688062)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.